Keywords
Pharmacological treatment
Self-medication
Risk of irrational use
Drug interactions
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the main risks in the irrational use of PPIs. Methods: This is an integrative review carried out using the BVS and SciELO health databases, with the search for scientific articles from 2011 to 2022, in Portuguese, English and Spanish, using the Health Sciences Descriptors (DeCS): Proton pump inhibitors; Risks of Irrational Use; Adverse effects; Drug Interactions and Pharmacological Treatment. Results: The search resulted in 25 articles, then a complete reading of the articles was carried out with the application of the inclusion and exclusion criteria, 11 articles that met the selection criteria were included. Conclusion: In addition to the pharmacological risks due to the prolonged use of PPIs, they have interactions with other drugs and foods, therefore they must be used with caution by individuals to avoid undesirable interactions during treatment. The chronic and indiscriminate use can bring many health complications, and caution must be exercised during medical prescription and guidance to users regarding the consequences attributed to prolonged use of PPIs in order to reduce the adverse effects caused and ensure the correct application of these drugs.
References
ARAI EA, GALLERANI SC. Uso crônico de fármacos inibidores da bomba de prótons: Eficácia clínica e efeitos adversos. Monografia (Especialização em farmacologia) - Centro Universitário Filadélfia, Londrina, 2011; 61p.
ARAÚJO LS, et al. Inibidores de Bomba de Prótons: vantagens e desvantagens do uso prolongado, Revista Eletrônica Acervo Científico, 2021; 34: e8662.
BARBOSA YV, et al. Uso prolongado e inadequado dos inibidores da bomba de prótons e seus efeitos na saúde dos idosos, Revista do Congresso Internacional de Envelhecimento Humano, 2020; 10(4): 4-8.
BAVISHI C, DUPONT HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection, Aliment Pharmacol Ther, 2011: 34(11-12): 1269-1281.
BRAGA PM, et al. Inibidores da bomba de prótons: Revisão e análise farmacoeconômica, Saúde (Santa Maria), 2012; 37(2): 19-32.
BETIOLO PC. Inibidores da bomba de prótons: Uma revisão dos riscos do uso por longo prazo e o padrão de dispensação em uma farmácia municipal no sul do Brasil, Repositório institucional, 2019; 19(4): 4-30.
BOARDMAN HF, HEELEY G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitor, international journal of clinical pharmacy, 2015; 37(5): 709-716.
GONZAGA CE, et al. Prevalence of self-medication for dyspepctic symptoms in primary care: a Brazilian survey, Arquivos de Gastroenterologia, 2021; 58(3): 364-369.
IVO ED. Uso de inibidores de bomba de prótons entre estudantes de medicina de uma instituição de ensino superior de Maringá-PR e as consequências à curto e longo prazo, Brazilian Journal Of Development, 2021; 7(9): 2-15.
KINOSHITA Y, et al. Advantages and disavantages of long-term proton pump inhibitor use, Journal Neurogastroenterology and Motility, 2018; 24(2): 182-196.
MELO IO, et al. Inibidores da bomba de prótons e carcinogênese: uma revisão da literatura, Revista Médica (São Paulo), 2021; 100(5): 2-7.
MORRIS N, NIGHOT M. Understanding the health risks and emerging concerns associated with the use of long-term próton pum inhibitors, Bulletin of the National Research Centre, 2023; 47(134): 1-13.
MORSCHEL CF. Uso de inibidores da bomba de prótons na progressão da doença renal crônica: um estudo retrospectivo, Instituto de Saúde Coletiva Repositório Institucional, 2019; 4(9): 15-43.
OCHOA D, et al. Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazol, BMC Pharmacology and Toxicology, 2020; 21(1): 14-141.
PORTER KM, et al. Associations of atrophic gastritis and proton-pump inhibitor drug use with vitamin B-12 status, and the impact of fortified foods, in older adults, The American Journal of Clinical Nutrition, 2021; 114(4): 1286-1294.
PIMENTA LR, et al. Uso indiscriminado de Omeprazol em idosos e a importância da atenção Farmacêutica, Revista eletrônica de trabalhos acadêmicos, 2016; 1(3): 304-317.
RIBEIRO RM, et al. Inibidores de bomba de prótons aumenta o risco de fratura óssea em pacientes com comorbidades: uma revisão, Research, Society and Development, 2022; 11(15): 6-13.
ROBINSON M, HORN J. Clinical Pharmacology of Proton Pump Inhibitors, Drugs, 2012; 63: 2739-2754.
SALGADO AL, et al. Uso indiscriminado da bomba de prótons em prescrições de medicamentos de uso contínuo, Brazilian Journal Of Heath Review, 2019; 2(6): 5883-5897.
SERAFIM LC, et al. A review of the role of flavonoids in peptic ulcer, Molecules, 2020; 25(22): 5431.
SOUZA IF, et al. Qualitative Analysis of anatomopathological changes of gastric mucosa due to long term therapy with proton pump inhibitors: experimental studies x clinical studies. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo), 2013; 26(4): 328- 334.
YOZGAT A, et al. Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19, Turkish Journal of Medical Sciences, 2021; 51(3): 1675-1681.